MRSN - Mersana Therapeutics, Inc.
| Previous Close | 3.5600 |
| Open | 3.7300 |
| Bid | 3.15 x 1000 |
| Ask | 3.23 x 900 |
| Day's Range | 2.8450 - 3.6250 |
| 52 Week Range | 2.8450 - 23.9570 |
| Volume | 383,708 |
| Avg. Volume | 114,626 |
| Market Cap | 76.502M |
| Beta (3Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.43 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.00 |
- American City Business Journals•13 days ago
Mersana CEO details path forward after breakup with Takeda
Mersana executives discussed data from its ovarian and lung cancer drug trial Wednesday. The biotech also plans to disclose its next clinical candidate in the second half of 2019.
- Simply Wall St.•19 days ago
Are Mersana Therapeutics, Inc.’s (NASDAQ:MRSN) Interest Costs Too High?
Mersana Therapeutics, Inc. (NASDAQ:MRSN), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MRSN Read More...
- MarketWatch•19 days ago
Mersana to discontinue development of one cancer treatment to focus on another
Biopharmaceutical company Mersana Therapeutics Inc. said Friday that it will discontinue development of its XMT-1522 cancer treatment, following a strategic evaluation by the company. The stock is currently halted for news. Instead, the company will focus its resources on advancing XMT-1536. XMT-1522 was being developed with its partner, Takeda Pharmaceutical Co. Ltd. . "We have made the difficult decision to terminate the further development of XMT-1522 despite a favorable emerging profile of efficacy and tolerability due to the competitive environment for HER2-targeted therapies," said Mersana Chief Executive Anna Protopapas. The company said it plans to report phase 1 trial dose escalation data in the first half of 2019. The stock has plunged 56% over the past three months, while the iShares Nasdaq Biotechnology ETF has lost 17% and the S&P 500 has shed 16%.
- GlobeNewswire•19 days ago
Mersana Therapeutics Announces Strategic Priorities and Goals for 2019 and Beyond
Mersana Therapeutics, Inc., (MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high unmet need, today announced that after a strategic evaluation the Company will prioritize its resources to focus on the advancement of XMT-1536, a first-in-class ADC candidate targeting NaPi2b. “While still in early clinical development, we are encouraged with the safety, tolerability, and activity of XMT-1536 as well as the pace at which the current study is advancing. For this reason, we have decided to focus our resources on advancing XMT-1536, our first-in-class ADC candidate targeting NaPi2b, a clinically validated ADC target broadly expressed in ovarian and non-small cell lung cancer (NSCLC) adenocarcinoma, for which there remains a significant unmet medical need,” said Anna Protopapas, President and CEO, Mersana Therapeutics.
- GlobeNewswire•21 days ago
Mersana Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 02, 2019 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•2 months ago
New Research: Key Drivers of Growth for Mersana Therapeutics, Maiden, Payment Data, CareDx, Natera, and Spero Therapeutics — Factors of Influence, Major Initiatives and Sustained Production
NEW YORK, Nov. 28, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., Nov. 27, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•2 months ago
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates
XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019 XMT-1522 Phase 1 Dose Escalation Enrollment Resumed Mersana to Present New.
- GlobeNewswire•2 months ago
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer
CAMBRIDGE, Mass., Nov. 12, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•2 months ago
Mersana Scientists Present Updates on XMT-1522, XMT-1536 and the Dolaflexin Platform at World ADC 2018
Mersana Chief Scientific Officer, Timothy B. Lowinger, Ph.D. to chair 2018 Conference CAMBRIDGE, Mass., Nov. 12, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a.
- GlobeNewswire•2 months ago
Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference
CAMBRIDGE, Mass., Nov. 08, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- GlobeNewswire•3 months ago
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates
CAMBRIDGE, Mass., Nov. 06, 2018 -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of.
- Motley Fool•4 months ago
Why Nio, Mersana Therapeutics, and Tandem Diabetes Care Slumped Today
Find out what took the energy out of these stocks.
Motley Fool•5 months agoMersana Therapeutics, Inc. (MRSN) Q2 2018 Earnings Conference Call Transcript
MRSN earnings call for the period ending June 30, 2018.
- ACCESSWIRE•5 months ago
Mersana Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 15, 2018 / Mersana Therapeutics, Inc. (NASDAQ: MRSN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 15, 2018 at 8:00 AM Eastern ...
